Studies among people with multiple sclerosis (pwMS) receiving disease-modifying therapies (DMTs) have provided adequate evidence for an appraisal of COVID-19 vaccination policies among them. To ...

Background Anti-N-methyl-D-aspartate receptor encephalitis (NMDARE) is a severe autoimmune disorder with high morbidity and mortality. Current treatments have limitations including relapse, ...

This May, the World Health Assembly (WHA) will vote on re-establishing a mandate for the WHO to address the health consequences of nuclear weapons and war.1 Health professionals and their associations ...

Correspondence to Professor Gen Sobue, Research Division of Dementia and Neurodegenerative Disease, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466 8550, Japan; ...

Hachem et al attempt to peer through the murky waters of the relationship between depression and dementia.1 Depression was identified as a potentially modifiable risk factor for dementia by the Lancet ...

Background Depression has been consistently linked to the onset of dementia, but the temporality and nature of this ...

Background Several prognostic models predict clinical outcomes in Guillain-Barré syndrome (GBS). Recently, neurofilament light chain (NfL) has emerged as a prognostic biomarker. We investigated the ...

Background and purpose To investigate early clinical surrogates for long-term independency of patients treated with thrombectomy for large vessel occlusion stroke in daily clinical routine. Methods ...

Disease-modifying treatments for major neurocognitive disorders, including Alzheimer’s disease, Parkinson’s disease and other cognitive deficits, are among the main unmet needs in modern medicine.

Correspondence to Dr Satoshi Kuwabara, Neurology, Chiba University School of Medicine, Chiba, Japan; kuwabara-s{at}faculty.chiba-u.jp CIDP is a most common chronic immune-mediated demyelinating ...